New insider activity at Exelixis ( (EXEL) ) has taken place on May 19, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Exelixis has reported a notable insider transaction as EVP & CFO Christopher Senner sold 75,793 shares of the company’s stock, generating total proceeds of $3,834,631. This sizable sale by a top executive may draw investor attention as they evaluate insider activity and its potential implications for the company’s outlook.
Recent Updates on EXEL stock
Exelixis shares reacted to its Q1 earnings call, where solid CABOMETYX-driven revenue, strong profitability, major buybacks, and a $1.4 billion cash position supported sentiment, but higher gross‑to‑net discounts and a sharp tax provision reminded investors of margin and earnings volatility. Analysts’ price target updates likely reflected this balance plus pipeline risk and upside, as ZANZA advances through multiple pivotal trials, new meningioma and RCC studies progress, and dependence on key readouts and partner-led programs adds uncertainty to the long-term valuation.
Spark’s Take on EXEL Stock
According to Spark, TipRanks’ AI Analyst, EXEL is a Outperform.
EXEL scores highly due to strong financial performance (very high margins, excellent cash conversion, and low leverage) and a supportive earnings-call backdrop (reiterated guidance, strong CABOMETYX momentum, and significant buybacks). Technicals are constructive with price above key moving averages and positive momentum. Valuation is reasonable on P/E, though the lack of a dividend yield limits that component’s upside.
To see Spark’s full report on EXEL stock, click here.
More about Exelixis
YTD Price Performance: 13.71%
Average Trading Volume: 2,808,197
Technical Sentiment Signal: Buy
Current Market Cap: $12.6B